Roth Capital resumed coverage on Moleculin Biotech with a new price target

2/1/21 11:22:36 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Roth Capital resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $29.00 from $5.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MBRX

Date	Price Target	Rating	Analyst
6/9/2025	$4.00	Buy	H.C. Wainwright
2/12/2025		Buy → Hold	Maxim Group
7/18/2022	$14.00	Outperform	Oppenheimer